ARTICLE | Company News
GeneThera, Oxford BioMedica cancer, gene/cell therapy, neurology news
August 25, 2008 7:00 AM UTC
Oxford BioMedica's board unanimously rejected an unsolicited offer by GeneThera to acquire the U.K. company for 35p per share, or about £140.8 million ($270.7 million) in stock. The price was a 305% p...